Combination therapy adding the dipeptidyl peptidase-4 (DPP-4) inhibitor, saxigliptin to concurrent metformin therapy for 12 weeks was found to increase CD31+ numbers (reflecting a mature circulating pool of endothelial cells) but not CD34+ in type II diabetes patients [81]. The gene discussed is CD34; the disease is type 2 diabetes mellitus.